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Malonylation of GAPDH is an inflammatory signal
in macrophages
Silvia Galván-Peña1,2, Richard G. Carroll3, Carla Newman4, Elizabeth C. Hinchy5, Eva Palsson-McDermott1,
Elektra K. Robinson6, Sergio Covarrubias 6, Alan Nadin7, Andrew M. James5, Moritz Haneklaus1,
Susan Carpenter6, Vincent P. Kelly 1, Michael P. Murphy 5, Louise K. Modis2 & Luke A. O’Neill1,2
Macrophages undergo metabolic changes during activation that are coupled to functional
responses. The gram negative bacterial product lipopolysaccharide (LPS) is especially potent
at driving metabolic reprogramming, enhancing glycolysis and altering the Krebs cycle. Here
we describe a role for the citrate-derived metabolite malonyl-CoA in the effect of LPS in
macrophages. Malonylation of a wide variety of proteins occurs in response to LPS. We
focused on one of these, glyceraldehyde-3-phosphate dehydrogenase (GAPDH). In resting
macrophages, GAPDH binds to and suppresses translation of several inflammatory mRNAs,
including that encoding TNFα. Upon LPS stimulation, GAPDH undergoes malonylation on
lysine 213, leading to its dissociation from TNFα mRNA, promoting translation. We therefore
identify for the first time malonylation as a signal, regulating GAPDH mRNA binding to
promote inflammation.
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Post-translational modifications (PTMs) are key to expand-ing the functional diversity of proteins and have animportant impact on protein function in health and dis-
ease1. Malonylation is a recently identified, evolutionarily con-
served modification2,3, wherein malonyl-CoA is used as a
substrate to add a malonyl group to the amino acid lysine2,4,5,
changing its charge from +1 to −1. This change is predicted to
disrupt electrostatic interactions with other amino acids and alter
protein conformation and binding to targets2. Malonylation
remains a poorly understood modification, with very few studies
having investigated its functional impact. It has been shown to
be present across various metabolic pathways, including fatty
acid synthesis and oxidation5,6, mitochondrial respiration5 and
glycolysis6,7, as well as being capable of modifying histones8. It
has also been recently linked to angiogenesis in endothelial cells
by modifying mTOR complex 1 (mTORC1) kinase activity9.
However, no further physiological function has yet been attrib-
uted to malonylation.
Several studies have recently highlighted the role of metabolic
reprogramming in determining the function of immune cells
(reviewed in ref. 10). Macrophages have been a particular focus in
this regard. These front line cells of innate immunity, inflam-
mation, and tissue repair11, display different metabolic features
depending on their function. Pro-inflammatory macrophages,
such as those activated by lipopolysaccharide (LPS), are highly
glycolytic with a disrupted Krebs cycle12,13. Succinate has been
shown to accumulate and drive production of reactive oxygen
species, leading to the activation of hypoxia-inducible factor-1α
and the induction of target genes, such as that encoding IL-
1β14,15. Another Krebs cycle intermediate, citrate, accumulates,
driving the production of inflammatory mediators, such as nitric
oxide and prostaglandins16, as well as the anti-inflammatory
metabolite itaconate17. The role of the malonylation substrate and
downstream metabolite of citrate, malonyl-CoA, is yet to be
explored in immune cells and inflammation. Malonyl-CoA is
synthesised in the cytosol from acetyl-CoA by acetyl-CoA car-
boxylase (ACC)18 or in the mitochondria from malonate by
ACSF34. There are two different ACC isoforms; ACC1 is reported
to be responsible for the production of malonyl-CoA in tissues
with high levels of lipid synthesis and when knocked out in mice,
it is embryonically lethal19. ACC2 is reported to be mostly
expressed in oxidative tissues, where it can inhibit fatty acid
oxidation via malonyl-CoA. ACC2 KO mice do not display
embryonic lethality, but are resistant to obesity and diet-induced
diabetes20. Interestingly, ACC1 has been recently shown to play a
role in the differentiation of human CD4+ T cells into effector
cells21, as well as in the mechanism of defense of Th1 cells against
Mycobacterium tuberculosis infection22.
Here, we characterise malonylated proteins in an immune cell
population. The malonylation response occurs in bone marrow-
derived macrophages (BMDMs) following cell activation and
relies on ACC1-dependent malonyl-CoA production. We found
that malonylation of the glycolytic enzyme GAPDH in particular,
has an impact on pro-inflammatory cytokine production, by
modulating both its enzymatic activity and RNA-binding capa-
city. This novel finding reveals a hitherto unknown mechanism in
LPS signalling that regulates the expression of central pro-
inflammatory mediators, while further emphasising the impor-
tance of metabolic reprogramming in macrophage activation.
Results
MalonylCoA alters cytokine production in macrophages. To
determine the role of malonyl-CoA in macrophages, we first set
out to measure its production in LPS-activated BMDMs, and
found it to be significantly increased following 24 h of LPS
treatment (Fig. 1a). In order to identify the source of malonyl-
CoA and be able to manipulate its levels, expression of the three
existing malonyl-CoA-synthesising enzymes was analysed. We
found the ACC1 isoform to be the highest expressed in BMDMs,
followed by ACSF3, while no expression of the ACC2 isoform was
detected. (Fig. 1b). We sought to compare our qPCR expression
data with the existing RNAseq data from different immune cell
types from the ImmGen consortium. The available RNAseq data
from macrophages supports our results, with no ACC2 (acacb)
expression detected and with ACC1 (acaca) being the highest
expressed enzyme of the three (Supplementary Fig. 1). Further-
more, to our surprise, macrophages appear to have up to 10 times
higher ACC1 expression than any other immune cell type
(Supplementary Fig. 1a). Similarly, while ACC2 appears to be
expressed in bone marrow immune stem cell precursors, it is not
expressed in most immune cells, with the exception of some B cell
populations, CD8+ T cells and FoxP3+ Treg cells (Supplementary
Fig. 1b).
We sought to manipulate malonyl-CoA levels in BMDMs by
knocking down ACC1 or ACSF3 using two independent siRNAs.
~50% knockdown (KD) of each enzyme was obtained as
measured by gene expression and confirmed at the protein level
in the case of ACC1 (Fig. 1c, d). ACC1 and ACSF3 KD resulted in
a 30–50% reduction in basal malonyl-CoA and a 70% reduction
in the LPS-elevated malonyl-CoA (Fig. 1e). Under these
conditions, we evaluated cytokine production in LPS-treated
BMDMs in order to assess what the functional consequences of
reduced malonyl-CoA might be. We found that both ACC1 and
ACSF3 KD decreased production of the pro-inflammatory
cytokine IL6 (Supplementary Fig. 2a, 2b), whilst simultaneously
boosting the production of the anti-inflammatory cytokine IL10
(Supplementary Fig. 2c, d). TNFα production was also reduced
but only in the ACC1 KD, and interestingly, the inhibitory effect
was only observed at the protein level (Fig. 1f), as TNFα
transcription was unaffected (Fig. 1g), both following 6 and 24 h
LPS treatment (Supplementary Fig. 2e). Next, to confirm that
the distinct effects on TNFα were malonyl-CoA dependent, we
sought to increase the metabolite’s levels within the cells by
treating them with malonyl-CoA. Treatment of BMDMs with
malonyl-CoA resulted in an increase in intracellular malonyl-
CoA levels (Supplementary Fig. 2g). Pre-treatment of ACC1 KD
BMDMs with malonyl-CoA was able to recover the decrease in
TNFα (Fig. 1h), thus confirming that malonyl-CoA can act as a
modulator of cytokine production in macrophages.
Activation of macrophages results in protein malonylation.
Given the increase in malonyl-CoA and the observed functional
consequences of inhibiting its production, we next investigated
protein malonylation in response to LPS, as this would be a likely
outcome of malonyl-CoA accumulation. As shown in Fig. 2a, LPS
increased overall lysine malonylation (mal-K) on multiple pro-
teins. Having tested the specificity of the antibody through pep-
tide competition (Supplementary Fig. 3), we proceeded to validate
this increase and identify the substrates of the LPS-induced
malonylation through mass spectrometry. Malonylated proteins
from untreated and LPS-treated macrophages were affinity pur-
ified and analysed via LC–MS/MS (Supplementary Fig. 4a, Sup-
plementary Data 1). More than 80% of proteins identified were
found to have a maximum of two malonylated sites on each
protein (Supplementary Fig. 4b). Label-free quantification23 was
applied to the 412 quantifiable proteins and 843 quantifiable sites
were identified on a range of proteins. Two hundred and eighty
sites were found to be upregulated by LPS in total. Seventy eight
of these were only found in LPS-treated samples, while 202 sites
were found to be upregulated by more than 1.5 fold by LPS
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compared to untreated, 98 of which were found to be statistically
significant (Supplementary Data 1, Supplementary Fig. 4b). The
majority of LPS-induced malonylated proteins are cytosolic, with
31% nuclear proteins, and only 7% mitochondrial proteins
(Supplementary Fig. 5a). Unlike previous studies, where mal-
onylation has mainly been shown to influence metabolic
enzymes5–7, a functionally diverse set of proteins was shown to
undergo malonylation in response to LPS, including proteins
involved in RNA regulation, signal transduction, immune sig-
nalling, and glycolysis (Fig. 2b, Supplementary Fig. 5b). One of
the proteins identified in the analysis was glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). This is a critical enzyme in
glycolysis but can also bind RNAs directly24,25, and regulate
translation within the interferon-γ-activated inhibitor of trans-
lation (GAIT) complex26. Given the role of glycolysis in LPS
action in macrophages, as well as its RNA-binding capacity,
we chose GAPDH as a good candidate to investigate the role of
LPS-induced malonylation in macrophage activation.
LPS induces malonylation of GAPDH at lysine 213. We
immunoprecipitated GAPDH from BMDM lysates and showed
that in agreement with the mass spectrometry results, LPS
strongly increased its malonylation by western blotting with an
anti-mal-K antibody (Fig. 2c, lower panel, compare lane 5 to lanes
6–8). GAPDH LPS-induced malonylation was observed no earlier
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Fig. 1 Activation of macrophages increases malonyl-CoA levels and is needed for pro-inflammatory cytokine production. aMalonyl-CoA levels measured in
untreated and LPS-treated (100 ng/mL) BMDM lysates using a malonyl-CoA ELISA. Mean+ SEM, n= 3. b ACC1, ACC2 and ACSF3 mRNA expression
measured via qPCR in BMDMs. Mean+ SEM, n= 3. c ACC1 siRNA (48 h, 10 nM) knockdown (KD) measured by western blotting in untreated and LPS-
treated (100 ng/mL, 24 h) BMDMs. β-actin used as a control. Representative of three independent experiments. d ACC1 and ACSF3 siRNA (48 h, 10 nM)
KD levels relative to control siRNA, measured via qPCR in untreated and LPS-treated (100 ng/mL, 24 h) BMDMs. Mean+ SEM, n= 4. e Malonyl-CoA
levels measured in ACC1 and ACSF3 KD BMDM lysates using a malonyl-CoA ELISA. Mean+ SD, representative of four independent experiments. f TNFα
protein measured by ELISA (mean+ SEM, n= 3) and g TNFαmRNA expression in 100 ng/mL LPS-treated (100 ng/mL, 6 h) ACC1 and ACSF3 KD BMDMs
(mean+ SD, representative of three independent experiments). h TNFα protein measured by ELISA in ACC1 KD BMDMs pre-treated with malonylCoA (1
mM, 2 h) followed by LPS (100 ng/mL, 6 h) (mean+ SD, representative of three independent experiments). Unpaired t-test, *P < 0.05; **P < 0.005
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than 6 h and seemed to gradually increase, with a much more
noticeable increase at 24 h. Furthermore, we also used the mal-
onylation chemical probe, malAMyne (Fig. 2d), and methodology
by X. Bao et al. 27, to label malonylated lysines in untreated and
LPS-treated BMDMs. This additional method further confirmed
that LPS strongly induced malonylation of GAPDH (Fig. 2e,
compare lane 4 to lane 3). In addition, we found that GAPDH
in vitro is highly sensitive to malonylation by low concentrations
of malonyl-CoA (Fig. 2f).
Seven malonylated sites had been originally identified on
GAPDH (Supplementary Data 1). We next sought to determine
which of these would be the most abundant and physiologically
relevant by immunoprecipitating endogenous GAPDH from
BMDMs and identifying the PTMs present by mass spectrometry.
In this manner, only two lysines were identified as undergoing
malonylation (Fig. 2g, Supplementary Fig. 6). Lysine 192 (K192)
was malonylated in GAPDH in resting macrophages, but
importantly lysine 213 (K213) underwent malonylation following
macrophage activation with LPS (Supplementary Data 2). Inter-
estingly, the same lysines were also found to be acetylated. The
residue K213 is highly conserved (Supplementary Fig. 7a). It is
present both, in the catalytic domain in close proximity to the
enzyme’s active site cysteine (Supplementary Fig. 7b), as well as
within the dimerisation region, in close proximity to the key
threonine residue previously linked to RNA-binding and GAPDH
dimerisation (Supplementary Fig. 7c)28.
We next aimed to address the potential mechanism of
malonylation. No malonyltransferase enzymes have yet been
identified, although both protein succinylation and malonylation
have been shown to be removed by the same enzyme29. We first
examined whether the recently identified succinyl transferase
KAT2A30 could be a malonyl-transferase for GAPDH. However,
we did not find KAT2A to interact with GAPDH (Supplementary
Data 3). Following LPS treatment at the time of GAPDH
malonylation, GAPDH was found to interact with the acetyl-
transferase p300, which has also recently been identified as a
crotonyl-transferase31, and might therefore be a good GAPDH
malonyl-transferase candidate32,33. On the other hand, it has
been previously shown that reactive cysteine residues can catalyse
the transfer of acyl groups from CoA onto proximal lysine
residues within the same protein34. As the active site cysteine
residue of GAPDH is within 18.4 Å of K213 (Supplementary
Fig. 7b), we hypothesised that K213 could be particularly
susceptible to malonylation due to its proximity. We found that
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rapid GAPDH in vitro malonylation could be prevented by
the alkylating agents iodoacetamide and methylmethanethiosul-
fonate, and more importantly, by the GAPDH inhibitor heptelidic
acid (HA), which selectively alkylates the active site cysteine
of GAPDH35 (Fig. 2h). These findings suggest that K213 is
particularly sensitive to malonylation in response to the elevation
of cytosolic malonyl-CoA upon LPS treatment, and might
indicate that GAPDH can perhaps catalyse its own malonylation
under certain conditions.
GAPDH is needed for cytokine production in macrophages.
We next explored the role of GAPDH malonylation on K213
during LPS activation in detail, first exploring the effect of mal-
onylation on GAPDH activity. Consistent with previous reports
showing that pro-inflammatory macrophages have increased
glycolytic flux12,36, the activity of GAPDH in LPS-treated mac-
rophages was increased after 24 h (Fig. 3a). No changes in protein
expression were detected (Supplementary Fig. 8a), however, we
had previously shown malonylation of GAPDH to be highest at
this time. Furthermore, inhibiting GAPDH enzymatic activity
with HA37 (Supplementary Fig. 8b), reduced transcription of
the pro-inflammatory cytokine pro-IL1β, to the same extent as
another glycolytic inhibitor, 2-deoxyglucose (2-DG), as shown
previously14 (Supplementary Fig. 8c). The induction of pro-IL1β
protein was also inhibited by HA (Supplementary Fig. 8d). IL6
mRNA and protein (Supplementary Fig. 8e, f) were also inhibited
by HA. Intriguingly, a different result was obtained with TNFα. A
clear inhibitory effect was observed at the protein level with HA
but not 2-DG (Fig. 3b). HA did not inhibit the induction of TNFα
mRNA however (Fig. 3c), while 2DG boosted TNFα mRNA
production. We further explored the role of GAPDH in cytokine
production using siRNA to KD GAPDH in BMDMs (Fig. 3d,
Supplementary Fig. 9a). Consistent with the inhibitory effect of
HA, KD of GAPDH with two independent siRNAs resulted in a
decrease in pro-IL1β (Fig. 3d, Supplementary Fig. 9b) and IL6
production (Supplementary Fig. 9c, d). GAPDH KD had how-
ever, the opposite effect on TNFα, the production of which was
boosted (Fig. 3e), while transcript levels remained unchanged
(Fig. 3f). These findings confirm a glycolysis-dependent regula-
tion of pro-IL1β and IL6, as shown by both glycolytic inhibitors
and GAPDH KD having the same effect. On the other hand, a
glycolysis-independent, post-transcriptional mechanism of reg-
ulation of TNFα production mediated by GAPDH is indicated by
the lack of effect of 2DG on TNFα. The inhibitory effect of HA on
TNFα protein production was intriguing, indicating that targeting
of GAPDH by HA would perhaps boost mRNA binding by
GAPDH, thereby repressing its post-transcriptional processing.
A possible mechanism is HA preventing GAPDH malonylation,
implying that malonylation could be a signal to dissociate
GAPDH from TNFα mRNA, allowing for its post-transcriptional
processing. The differing effects of 2DG, HA and GAPDH KD are
depicted in Supplementary Fig. 9e. By attenuating glycolysis,
induction of IL1β is blocked, as expected. Glycolysis per se has no
role in TNFα production, however, GAPDH represses TNFα,
possibly because of RNA binding blocking translation. LPS
relieves this repression by causing the dissociation of GAPDH
from the mRNA, which requires GAPDH malonylation.
GAPDH regulates TNFα production via RNA-binding. To test
the possibility that GAPDH may be post-transcriptionally
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regulating TNFα production directly, we turned our attention to
RNA-binding by GAPDH. GAPDH has been previously reported
to bind mRNA transcripts containing AU-rich elements38,39, which
are present in TNFα40,41, as well as IFNγ mRNAs42. It has also
been shown to be part of the GAIT complex, which mediates
translational repression of GAIT element-containing transcripts26.
We first immunoprecipitated GAPDH from BMDMs and exam-
ined bound RNAs by qPCR. GAPDH in resting macrophages
was found to bind the RNA of TNFα (Fig. 4a). Following 6 h
activation with LPS, there was a significant reduction in binding
to TNFα RNA, and following 24 h, GAPDH binding could no
longer be detected (Fig. 4a). Similarly, in resting macrophages
GAPDH bound to mRNA for the GAIT-element-containing death-
associated protein kinase-1 (DAPK1) and dissociated following
LPS treatment (Supplementary Fig. 10a). Enhanced translation
appeared likely to be a key mechanism for TNFα and DAPK1
production, since there was a clear discrepancy between mRNA
and protein induction for both genes. Both TNFα and DAPK1
mRNA levels were low when protein was high (Fig. 4b, Supple-
mentary Fig. 10b). The 3′-untranslated region (UTR) of both genes
was also repressive as they both inhibited reporter expression from
luciferase vectors expressing DAPK1 and TNFα 3′-UTRs (Sup-
plementary Fig. 10c). To validate that BMDMs are actively trans-
lating and secreting TNFα after the initial LPS stimulus, cells were
treated with LPS for 4 and 8 h. The LPS-containing media was then
removed, replaced with fresh media not containing any LPS, and
the supernatants were harvested 24 h after the original LPS sti-
mulus. Despite the cells having been without LPS for 20 and 16 h,
respectively, they were still able to synthesise and secrete TNFα
(Fig. 4c), indicating that the increase in TNFα production over time
depicted in Fig. 4b is not due to continuous TNF α transcription in
response to direct LPS sensing. Furthermore, we also investigated
the translation efficiency of Tnfα in primary BMDMs pre-LPS and
post-LPS stimulation by evaluating relative polysome enrichment
(Supplementary Fig. 11). RNA was isolated from 80S (monosomes),
low-molecular-weight and high-molecular-weight fractions. Gapdh
mRNA, which is not regulated by LPS treatment, was studied as a
high polysome control, while Neat1, a long noncoding RNA
(lncRNA), was studied as an 80S polysome control. Under these
settings we found Tnfα mRNA to be enriched in the low polysome
fraction with a marked increase in enrichment in the LPS-treated
samples (Supplementary Fig. 11d), indicating that there is active
TNFα translation in LPS-treated macrophages at the time of
GAPDH malonylation. In addition, we found that following LPS
treatment, GAPDH can be found directly interacting with various
ribosomal components (Supplementary Fig. 12a, Supplementary
Data 3), which would indicate GAPDH is able to directly transfer
the RNA onto the translation machinery to enable translation.
Overall, we have observed TNFα protein production to be
enhanced in BMDMs when GAPDH was knocked down,
GAPDH dissociating from the TNFα mRNA in response to
LPS, as well as interacting with the translation machinery at
the time of active TNFα translation. All these results taken
together support a role for GAPDH as an RNA-binding protein
responsible for suppressing translation in resting macrophages,
and dissociating from target mRNAs in response to LPS.
We next sought to determine whether malonylation of
GAPDH might be involved in GAPDH dissociation from target
mRNAs. GAPDH protein expression is not affected by LPS
treatment (Fig. 4d), suggesting that PTMs might indeed be the
mechanism by which LPS could alter GAPDH activity. Treatment
of BMDMs with HA prior to LPS, which would prevent GAPDH
malonylation, resulted in a profound increase in binding of
GAPDH to TNFα (Fig. 4e) and DAPK1 mRNA (Supplementary
Fig. 12b), as shown by GAPDH RNA-immunoprecipitation.
These results therefore might explain why HA can block TNFα
production, as it will maintain GAPDH in its unmalonylated state
on the TNFα 3′-UTR and suppress its translation.
Malonylation of GAPDH controls the enzyme’s activities.
Having identified GAPDH as a two-way regulator of cytokine
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production in activated macrophages, we next set out to identify
the mechanism behind GAPDH activities. Our data in Fig. 1e
supported a role for GAPDH malonylation in TNFα production,
since reduced malonyl-CoA levels in ACC1 KD cells also resulted
in reduced TNFα production in response to LPS. GAPDH
expression was unaffected in ACC1 KD and ACSF3 KD BMDMs
(Supplementary Fig. 13a, b), however the activity of GAPDH was
reduced in LPS-treated ACC1 KD cells (Fig. 5a). This implied
that malonylation of GAPDH frees the enzyme from bound
mRNA enabling it to enhance glycolytic flux. The same was not
the case in ACSF3 KD, where activity of GAPDH was unaffected
(Supplementary Fig. 13c). ACSF3-derived malonyl-CoA and
subsequent malonylation are confined to the mitochondria4,
while GAPDH is present in the cytosol, thus explaining the
observed differences. Consistent with our results demonstrating
that LPS both increased GAPDH enzymatic activity while
decreasing GAPDH RNA-binding, these activities have been
previously demonstrated to be mutually exclusive38,39. The evi-
dence therefore indicates that ACC1-derived malonyl-CoA is
needed for GAPDH malonylation, which in turn is needed for
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TNFα production via dissociation from its 3′-UTR, as well as for
its increased enzymatic activity.
To address the role of GAPDH K213 malonylation specifically
in these two activities, a K213 glutamine mutant (K213Q) was
generated. K213Q acts both as an acetylation mimic and as a
control, being unable to undergo malonylation. We also generated
a K213 glutamate (K213E) mutant, to act as a malonylation
mimic7. We first determined the effect of these mutations on
GAPDH enzymatic activity by affinity purifying them from
transfected HEK293T cells (Supplementary Fig. 14a, b) and
assaying them. The K213E mutant was found to have much higher
enzymatic activity than both WT and K213Q (Fig. 5b). This
supported the idea that malonylation would have the ability to
positively affect enzymatic activity by suppressing its mRNA
binding. We next investigated the RNA-binding capacity of the
GAPDH mutants, overexpressing them in HEK293T cells in
which endogenous GAPDH had been knocked down (Fig. 5c). In
direct opposition to the enzymatic activity, the K213E could not
bind TNFα mRNA, in contrast to the K213Q mutant and wild
type (Fig. 5d). These results taken together indicate that malonyla-
tion of K213 increases GAPDH enzymatic activity, while blocking
its binding to target mRNAs. This increased enzymatic activity
and reduced RNA-binding within macrophages, enables the
production of pro-inflammatory cytokines in response to LPS.
GAPDH is needed for IL1β production because of the role of
glycolysis in the process, and it must also dissociate from the
TNFα mRNA in order for TNFα translation to occur. We
therefore report a role for GAPDH malonylation on K213 in the
translation of LPS-induced genes, notably that encoding TNFα.
This scenario is depicted in Fig. 5e.
Discussion
PTMs play an essential role in the regulation of protein activity
and function across cellular systems, and despite their different
functional impacts, the great majority of them share their
origins in metabolic intermediates. Metabolic reprogramming in
immune cells has repeatedly been shown to be key for immune
function in recent years, and yet the connection between meta-
bolic changes and PTMs remains a very poorly understood
area. Our study reports the role of the post-translational mod-
ification malonylation in macrophage function. We have identi-
fied multiple proteins with a wide range of functions ranging
from metabolism, to cell death, to immune responses, as under-
going malonylation following activation of cells with LPS.
This effect is dependent on malonyl-CoA production by one of
the two ACC isoforms, ACC1, which is highly expressed in
macrophages. We propose a model whereby the previously
reported accumulation of citrate in activated macrophages13,
exits the mitochondria and following conversion into acetyl-CoA,
it is used to generate malonyl-CoA by ACC1 in the cytosol
which in turn, can act as a substrate for malonylation of multiple
substrates. LPS does not have any effect on ACC1 expression
levels, indicating that the increase in malonyl-CoA production
observed is likely the result of LPS modulating the enzyme’s
activity. Citrate has been shown to be able to allosterically reg-
ulate ACC activity directly43, so the reported accumulation of
citrate in activated macrophages might be the mechanism for
the observed effects. Interestingly, we find no expression at all
of the second ACC isoform, ACC2, an observation which is
based on the currently available RNAseq data, and might not
be restricted to just macrophages but to most immune cells.
ACC1 is generally found in tissues where fatty acid synthesis
is important, while ACC2 is associated with tissues with pre-
dominant oxidative metabolism. Their expression pattern thus
fits with the existing literature showing fatty acid synthesis is
upregulated and needed for function in macrophages44,45, den-
dritic cells46 and T cells21,22,47,48. In addition, oxidative phos-
phorylation has been shown to be inhibited by nitric oxide49,
which is a hallmark of activated pro-inflammatory dendritic cells
and macrophages49,50, which might explain the absence in ACC2
expression.
While we have presented ACC1 as the source of malonyl-CoA
for the malonylation reaction, the precise molecular details of
the modification remain to be elucidated. The only known reg-
ulator of malonylation is sirtuin 5, which can act not only as a
demalonylase, but can also remove similar acylations, such as
succinylation and glutarylation29,51. It is usually the case that
deacylases and acyl-transferases, as with sirtuin 5, can catalyse
the removal or addition of closely similar acylations. Recently,
two known acetyltransferases, KAT2A and p300, have been
identified as the first succinyltransferase and crotonyltransferase,
respectively30,31. It is possible that one of the existing acyl-
transferases may be capable of catalysing the malonylation reac-
tion as well. On the other hand, malonylation may be entirely
dependent on the available pool of malonyl-CoA and affinity for
different proteins. Given the increasing number of newly dis-
covered metabolically derived modifications in the last decade, we
predict the identification of enzymes and mechanisms behind
these, to be an exciting area of research in the coming years.
We have identified the glycolytic enzyme GAPDH as one
of the LPS-induced malonylated substrates in macrophages,
undergoing malonylation of a specific lysine within its catalytic
domain, lysine 213. While it has been reported numerous times
that activated macrophages display increased glycolysis, studies
into the role of GAPDH itself are lacking. The evidence we have
presented here indicates that following macrophage activation,
malonylation increases GAPDH enzymatic activity, enabling
the production of pro-inflammatory cytokines, including IL1β
and IL6. At the same time, we have shown that GAPDH can also
bind RNAs, including that of TNFα, with this being the first
report to our knowledge of malonylation affecting a protein
function beyond enzymatic activity. GAPDH binds AU-rich
elements in the 3′UTR of mRNA, an activity that is reported to
have two possible outcomes; on the one hand, it may result in
mRNA stabilisation, thus enabling translation, as is the case for
GAPDH binding to colony stimulating factor 1 in ovarian cancer
cells52. On the other hand, GAPDH binding may sequester the
mRNA and prevent translation, as has been shown to be the case
for IFNγ in T cells. Binding of GAPDH to TNFα mRNA in
macrophages occurs as per the latter. In resting cells without a
need for TNFα production, the mRNA is sequestered, thus pre-
venting its translation. Following a few hours of LPS activation,
if the cell finds itself still in need for TNFα production, the
GAPDH-bound pool of TNFα mRNA is released and translated,
enabling the amplification of the TNFα response, while at the
same time freeing GAPDH to engage in glycolysis, resulting in
a two-way wave of pro-inflammatory cytokine production.
Interestingly, protein translation has been identified as one of the
main biological functions influenced by malonylation in bacteria,
where GAPDH K213 has also been identified as undergoing
malonylation53, indicating that this process is likely to be evo-
lutionarily conserved.
In the present study, we have therefore identified malonylation
as a novel mechanism by which macrophages can control the
production of pro-inflammatory cytokines through GAPDH.
A role for our identified model in various inflammatory settings
is supported by recent reports. Administration of GAPDH in
a mouse model of sepsis, has been shown to have anti-
inflammatory effects by reducing TNFα54, with our study pro-
viding a possible mechanism for this repressive effect. In mouse
models of type 2 diabetes, GAPDH was shown to be
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hypermalonylated, which includes increased malonylation of
K2136. Targeting GAPDH through HA has also been shown to
be beneficial in mouse models of breast cancer55. Furthermore, a
recent study indicating that dimethylfumarate targets the active
site cysteine in GAPDH and thereby elicits its effects as therapy
in multiple sclerosis56, further emphasises the importance of
GAPDH for inflammation. Further characterisation of this post-
translational modification is likely to advance our understanding
of underlying processes in infection and inflammation, and
potentially indicate new therapeutic strategies to limit inflam-
mation in disease.
Methods
Reagents. LPS was from Alexis. A/G plus agarose beads, streptavidin beads and
biotin azide were obtained from Thermo Fisher. Sequencing grade modified trypsin
was purchased from Promega. Heptelidic acid was bought from Abcam. Lipo-
fectamine RNAiMax and Lipofectamine 2000 transfection reagents were obtained
from Invitrogen. Malonyl-CoA, 2-deoxyglucose, anti-FLAG M2 affinity gel and
3X FLAG peptide were obtained from Sigma. Anti-malonyl-lysine (PTM-901),
anti-GAPDH (MAB374), anti-GAPDH (ab8245), anti-IL1β (AF-401-NA), anti-
ACC1 (4190) and anti-DAPK1 (3008) antibodies were obtained from PTM Biolabs,
Merck, Abcam, R&D and Cell Signalling, respectively. Anti-β-actin (A3853), anti-
myc (M4439), mouse IgG (5381) and rabbit IgG (15006) were obtained from
Sigma. Peroxidase-conjugated anti-mouse, anti-rabbit and anti-goat secondary
antibodies were purchased from Jackson Immunoresearch. Odyssey anti-mouse,
anti-rabbit and anti-goat secondary antibodies were obtained from LiCOR Bios-
ciences. HEK293T cell line was obtained from ATCC. All other reagents, unless
otherwise especified, were obtained from Sigma.
Mice and cell culture. C57BL/6 mice were purchased from Harlam UK and
maintained in GSK or Trinity Biomedical Science Insitute animal facilities under
specific pathogen-free conditions. All animal studies were ethically reviewed
and carried out in accordance with European Directive 86/609/EEC and the
GSK Policy on the Care, Welfare and Treatment of animals.
Bone marrow cells were isolated from wild-type mice and differentiated in
DMEM with 10% foetal bovine serum, 1% penicillin/streptomycin and 20%
L929 supernatants for 6 days to generate BMDMs.
HEK293 cells were obtained from ATCC.
Protein immunoprecipitation and western blotting. A total of 10 × 106 cells/
condition were lysed in low stringency buffer (50 mM HEPES pH 7.5, 100 mM
NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP40) with protease inhibitors. Protein
concentration was measured using a BCA protein assay (Thermo Fisher) and
normalised across samples prior to immunoprecipitation.
One millilitre of lysates were pre-cleared with 15 μL A/G beads for 30 min at
4 °C. For GAPDH immunoprecipitation, 3 μg of antibody pre-coupled to beads
were added to lysates for 4 h at 4 °C. For mal-K immunoprecipitation, 9 μg of
antibody and 50 μL of A/G beads were added overnight at 4 °C. Lysates were
centrifuged for 3 min at 4 °C, the liquid was removed, and the beads were washed
three times with low stringency buffer. Immune complexes were eluted by adding
30 μL of 5X Laemmli sample buffer and boiling for 5 min at 95 °C.
Protein samples from cultured cells were prepared by direct lysis of cells in 5X
Laemmli sample buffer, followed by heating at 95 °C for 5 min. Protein samples
were separated by SDS–PAGE and transferred to nitrocellulose or PVDF
membranes via wet or iBlot (Invitrogen) transfer. Membranes were probed with
the respective antibodies and visualised using LumiGLO enhanced
chemiluminescent (ECL) substrate (Cell Signalling) or the Odyssey system. All
primary antibodies were used in a 1:1000 dilution, with the exception of the anti-β-
actin antibody, which was used in a 1:10,000 dilution. Secondary HRP-conjugated
antibodies were used in a 1:2000 dilution and Odyssey secondary antibodies were
used in a 1:10,000 dilution. The western blots for the enzyme assays were quantified
using the Image Studio software from Odyssey, also used for obtaining the
intensity ratios between GAPDH expression and β-actin.
Uncropped western blots from the main figures have been provided with the
supplementary information (Supplementary Fig. 15).
MalAMyne labelling and Cu(I)-catalysed click chemistry. The MalAMyne
chemical probe was synthesised as described by X. Bao et al. 27. Cells were labelled
with 10 µM MalAMyne or DMSO for 2 h. They were lysed and MalAMyne coupled
to biotin through Cu(I)-catalysed click chemistry followed by streptavidin affinity
enrichment as previously described 18.
Malonylation mass spectrometry. BMDMs were lysed in 8 M urea, 2 mM EDTA,
10 mM DTT, 1% Protease Inhibitor Cocktail, 2 µM TSA and 10 mM NAM, and cell
debris removed by centrifugation at 20,000×g at 4 °C for 10 min. Proteins were
precipitated with cold 15% TCA for 2 h at −20 °C, and then washed with cold
acetone three times. Proteins were dissolved in 8M urea, 100 mM NH4HCO3, pH
8, and protein concentration measured using a BCA protein assay (Thermo Fisher).
Protein concentration was normalised across samples.
Samples were reduced with 10 mM DTT, alkylated with 20 mM IAA and
urea concentration reduced to 2M using 100 mM NH4HCO3 followed by an
overnight trypsin digestion. Tryptic peptides were then dissolved in NETN buffer
(100 mM NaCl, 1 mM EDTA, 50 mM Tris–HCl, 0.5% NP-40, pH 8) and were
incubated with pre-washed anti-malonyl-K antibody beads (PTM Biolabs) at 4 °C
overnight. The beads were washed four times with NETN buffer and twice with
ddH2O. Bound peptides were eluted from the beads with 0.1% TFA, cleaned with
C18 ZipTips (Millipore) following manufacturer’s instructions, and analysed by
LC–MS/MS.
Three parallel analyses for each fraction were performed. Peptides were
dissolved in 0.1% formic acid and loaded onto a reversed-phase pre-column,
Acclaim PepMap 100 (ThermoFisherScientific) and separated using a Acclaim
PepMap RCLC (ThermoFisherScientific) at 700 nL/min in a gradient of 9–23%
organic (0.1% FA in acetronilile) in 40 min, then followed by 12 min from 23%
organic to 37% organic and finishing at 80% organic for 4 min. The samples were
run on a Orbitrap Fusion (ThermoFisherScientific) coupled to a NanoEasy LC
1000. The resolution of the isntrument was set to 60,000 for MS, and data-
dependent acquisition was performed, selecting the 20 most intense ions for
MS/MS, the MS/MS resolution was set to 15,000.
The resulting MS/MS were processed using Maxquant search engine (v.1.5.2.8).
Tandem mass spectra were searched against Swissprot Mus musculus database
concatenated with reverse decoy database. Trypsin was specified as the cleavage
enzyme allowing up to four missed cleavages. Main search range was set to 5 ppm
and 0.02 Da for fragment ions. Carbamidomethyl on Cys was specified as fixed
modification and malonyllysine on Lys and oxidation on Met were specified as
variable modifications. Label-free quantification was performed using the
Maxquant LFQ algorithm57, by comparing the abundance of the same peptides
across runs, with both ion intensities and spectral counts used for this purpose.
Mass spectrometry analysis was performed blindly by PTM Biolabs.
GAPDH PTMs mass spectrometry. For the identification of PTMs present in
GAPDH, GAPDH was immunoprecipitated from 1mg of BMDM lysates as
previously described, and IP samples were separated on 4–12% SDS–PAGE gels,
Coomasie stained, and bands of interest, together with their respective control
bands, excised from the gel. Gel pieces were trypsin-digested and peptides dissolved
in 1% TFA and injected onto a C18 spray tip and analysed by Q Exactive—
Orbitrap mass spectrometer. The raw data was searched in Mascot. Trypsin was
specified as the cleavage enzyme allowing up to one miscleavage and carbamido-
methylation on cysteines specified as a fixed modification. Acetylation, succinyla-
tion, malonylation, ubiquitination and phosphorylation were specified as variable
modifications.
Mass spectrometry analysis was performed blindly by PTM Biolabs.
ELISAs and MSDs. Cell culture supernatants were assayed for TNFα, IL6 and IL10
by ELISA (R&D) or by multiplex Meso Scale Discovery (MSD). MalonylCoA from
lysates was assayed by ELISA (Cusabio).
RNA extraction, reverse-transcriptase PCR and qPCR. RNA was extracted using
an RNeasy kit (Qiagen) and 250–1000 pg used for cDNA synthesis using a high
capacity cDNA reverse transcription kit (Applied Biosystems). For qPCR, Taqman
gene expression primers were used (Applied Biosystems), with expression of the
target gene normalised to the geometrical mean of the expression of β-actin,
18S and GAPDH.
siRNAs, mutagenesis and plasmids. GAPDH siRNAs (s234321 and s103461),
ACC1 siRNAs (s98860 and s98862) and ACSF3 siRNAs (s110944 and s110945)
together with a silencer® select negative control (4390843), were obtained from
Ambion. They were transfected into BMDMs seeded at 0.5 × 106 cells/mL at a
concentration of 10 nM using Lipofectamine RNAiMax.
The following stealth siRNA duplex was used to KD human GAPDH:
Sense: CAUGUACCAUCAAUAAAGUACCCUG
Antisense: CAGGGUACUUUAUUGAUGGUACAUG
The following primers were used for mutagenesis reactions using the
Quickchange II site-directed mutagenesis kit (Agilent Technologies):
GAPDH K213Q F: CTACTGGTGCTGCCCAGGCTGTGGGCAAGG
GAPDH K213Q R: GATGACCACGACGGGTCCGACACCCGTTCC
GAPDH K213E F: CTACTGGTGCTGCCGAGGCTGTGGGCAAGG
GAPDH K213E R: GATGACCACGACGGCTCCGACACCCGTTCC
The myc-DKK-GAPDH plasmid from Origene Technologies (Rockville, MD)
(RC202309) was used as the template for mutagenesis and as the wild-type in
experiments. psi-CHECK2 plasmid (Promega) was used for luciferase assays.
Luciferase assay. Five hundred nanograms of psiCHECK2, psiCHECK2-3’UTR-
dapk1 and psiCHECK2-3’UTR-tnfa were transfected into HEK293T cells using
Lipofectamine 2000. Forty-eight hours post-transfection cells were lysed with
1X passive lysis buffer (Promega). Forty microlitres of coelenterazine solution
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(1 μg/mL, Promega) was added to 20 μL of lysate and read immediately on a
luminometre to measure the renilla luciferase activity. Forty microlitres of 1X
luciferase mix (2×: 20 mM Tricine; 2.67 mM MgSO4⋅7H2O; 0.1 mM EDTA; 33.3
mM DTT; 530 μM ATP; 270 μM acetyl CoA; 470 μM D-Luciferin; 5 mM NaOH;
267 μM magnesium carbonate hydroxide) was added to 20 μL of lysate and the
plate read immediately to measure the firefly luciferase activity.
RNA-IP. BMDMs (10–20 × 106 cells/condition) were fixed with 1% formaldehyde
and then neutralised with 1 M glycine. Cells were washed with PBS and lysed in
polysome lysis buffer (0.1 M Hepes, 0.1 M KCl, 5 mM MgCl2, 0.5% NP40, 1 mM
DTT, 1X Protease Inhibitors). Five micrograms of GAPDH antibody or IgG
control were pre-coupled to 50 μL of A/G beads and added to lysates. The samples
were left rotating at 4 °C for 6 h. The beads were precipitated and washed at 4 °C
five times with polysome lysis buffer.
After the last wash, the protein–RNA complexes were eluted with 85 μL of
protein–RNA elution buffer (0.1 M Tris–HCl pH 8, 0.01 M EDTA, 1% SDS) and
samples incubated at 37 °C twice. The eluates were then removed from the beads
and 3 μL 5M NaCl and 10 μg Proteinase K added. Samples were then incubated at
42 °C for 45 min to digest cross-linked peptides and then incubated for 1 h at 65 °C
to reverse formaldehyde cross-links. The RNA was then extracted using phenol:
chloroform extraction.
GAPDH affinity purification and enzyme assay. The chromatography columns
were first rinsed with TBS (50 mM Tris–HCl, 150 mM NaCl, pH 7.4) twice, and the
columns were then packed with 1 mL ANTI FLAG M2 affinity gel. The column was
washed with 1 mL 0.1 M glycine HCl pH 3.5, three times, and then washed with 1
mL TBS five times.
A total of 107 HEK293T cells overexpressing FLAG-GAPDH were lysed using 1
mL lysis buffer (50 mM Tris–HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1%Triton)
and 1X proteiase inhibitor. lysates were run through the column up to five times.
The column was then washed 15 times with TBS. FLAG-GAPDH was eluted off the
column by adding 5 mL of a 100 μg/mL 3X FLAG peptide solution.
GAPDH enymatic activity was assayed using a colorimetric GAPDH activity
assay (Abcam).
Polysome profiling. Prior to lysis, cells were treated with cycloheximide (100 mg/
mL), 10 min at 37 °C 5% CO2. Cells were washed three times with ice cold PBS and
lysed in ice cold buffer A (0.5% NP40, 20 mM Tris–HCl pH 7.5, 100 mM KCl and
10 mM MgCl2). Lysates were passed three times through a 23 G needle and
incubated on ice for 7 min. Extracts were then centrifuged at 10 krpm for 7 min at
4 °C. The supernatant was collected as crude cytosolic extract. Cytosolic extracts
were overlaid on 10–50% sucrose gradients prepared in 20 mM Tris–HCl pH 7.5,
100 mM KCl and 10 mM MgCl2 buffer (prepared using the Gradient Station,
Biocomp Instruments). Gradients were then ultracentrifuged at 40 krpm for 1 h 20
min at 4 °C using an SW41 in a Beckman ultracentrifuge. Individual polyribosome
fractions were subsequently purified using a Gradient Station (Biocomp Instru-
ments). Total cellular RNA from BMDM cell lines or tissues was isolated using the
Direct-zol™ RNA MiniPrep Kit (Zymo Research) according to manufacturer’s
instructions. RNA was quantified and controlled for purity with a nanodrop
spectrometer. (Thermo Fisher). For RT-qPCR, 500–1000 ng were reversely tran-
scribed (iScript Reverse Transcription Supermix, Biorad) followed by RT-PCR (iQ
SYBRgreen Supermix, Biorad) using the cycling conditions as follows: 50 °C for 2
min, 95 °C for 2 min followed by 40 cycles of 95 °C for 15 s, 60 °C for 30 s and 72 °C
for 45 s. The melting curve was graphically analysed to control for nonspecific
amplification reactions. Quantitative RT-PCR analysis was performed with the
following primers listed below:
Neat1 F: TTGGGACAGTGGACGTGTGG
Neat1 R: TCAAGTGCCAGCAGACAGCA
Gapdh F: CCAATGTGTCCGTCGTGGATC
Gapdh R: GTTGAAGTCGCAGGAGACAAC
Tnfα F: CAGTTCTATGGCCCAGACCCT
Tnfα R: CGGACTCCGCAAAGTCTAAG
Statistical analysis. Statistical tests were performed using GraphPad prism. A
value of p < 0.05 was considered statistically significant.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Any further data not included in the manuscript is available from the corre-
sponding author on reasonable request.
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